Last update 20 Mar 2025

BMS-986416

Overview

Basic Info

Drug Type
Antibody fusion proteins
Synonyms
Target
TGF-β1 x TGF-β3
Action
inhibitors
Mechanism
TGF-β1 inhibitors(Transforming growth factor beta 1 inhibitors), TGF-β3 inhibitors(Transforming growth factor beta 3 inhibitors)
Therapeutic Areas
Neoplasms
Active Indication
Advanced Malignant Solid Neoplasm
Inactive Indication-
Originator Organization
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
Active Organization
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with BMS-986416
CTIS2022-501317-31-00
/ Not yet recruitingPhase 1
- CA102-003
NCT04943900
/ Active, not recruitingPhase 1
A Phase 1 Study of BMS-986416 Alone and in Combination With Nivolumab in Select Solid Tumors
100 Clinical Results associated with BMS-986416
Login to view more data
100 Translational Medicine associated with BMS-986416
Login to view more data
100 Patents (Medical) associated with BMS-986416
Login to view more data
100 Deals associated with BMS-986416
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 1
Argentina
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
09 Aug 2021
Advanced Malignant Solid NeoplasmPhase 1
United States
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
09 Aug 2021
Advanced Malignant Solid NeoplasmPhase 1
Belgium
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
09 Aug 2021
Advanced Malignant Solid NeoplasmPhase 1
Chile
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
09 Aug 2021
Advanced Malignant Solid NeoplasmPhase 1
Canada
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
09 Aug 2021
Advanced Malignant Solid NeoplasmPhase 1
Netherlands
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
09 Aug 2021
Advanced Malignant Solid NeoplasmPhase 1
Japan
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
09 Aug 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free